Press Releases
Record date for the distribution of warrants of series TO4 to current shareholders is set to November 19, 2020
November 16, 2020 14:59 (CET)RegulatoryOn November 10 2020, the board of directors of Cyxone AB (publ), (“Cyxone” or the “Company”) decided to carry out a Directed Issue (the “Directed Issue”), and to issue warrants of series TO4 to the current shareholders of Cyxone who on the record date holds shares in the Company. The warrants will, to some extent, compensate the current shareholders in the Company for the dilution in the Directed Issue.
Read moreCyxone presents at BioStock Life Science Summit 17-18 November 2020
November 16, 2020 08:54 (CET)CEO Tara Heitner will present the latest updates in Cyxone on 18 November at 14.35 at the online event BioStock Life Science Summit. Information about the event together with the agenda is found on the event’s webpage (https://www.summit.biostock.se/). Follow the presentation live here (https://www.youtube.com/watch?v=mjDcf7xyJx8&feature=youtu.be).
Read moreInterim Report 1 January to 30 September 2020
November 13, 2020 08:30 (CET)RegulatorySummary of the interim report
Read moreThe board of directors of Cyxone have decided to carry out a directed issue of units of approximately SEK 19 million and an issue of warrants to current shareholders
November 10, 2020 23:15 (CET)RegulatoryNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.
Read moreCyxone intends to carry out a directed issue of units
November 10, 2020 19:00 (CET)RegulatoryNOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE.
Read moreCyxone files patent application to extend exclusivity of Rabeximod
November 10, 2020 16:31 (CET)RegulatoryCyxone (publ.) announced today that the company has filed for an extended patent protection of Rabeximod with the European Patent Office (EPO), that will be extended to other territories in due course. An approval of the application will strengthen the company’s intellectual property portfolio and generate a longer market exclusivity for Rabeximod.
Read moreCyxone announces positive results from regulatory toxicology studies of Rabeximod
October 30, 2020 09:45 (CET)RegulatoryCyxone (publ.), a Swedish biotech company developing disease modifying therapies for disorders of the immune system, today announced that the six-month regulatory toxicology studies of its drug candidate Rabeximod has been successfully concluded. A read-out of the study results shows a favorable safety profile for Rabeximod, thus enabling longer clinical studies in patients up to six months. Cyxone will now take the next step toward the initiation of a Phase 2 study in rheumatoid arthritis patients.
Read moreCyxone further strengthens the team to reinforce the development projects
October 5, 2020 13:45 (CEST)Cyxone (publ.), a Swedish biotech company dedicated to developing improved treatments for autoimmune diseases, today announced the recruitment of Sally Abdelmoaty as Project Manager to focus on the next step in the development of Cyxone's drug portfolio. The recruitment will strengthen Cyxone’s capabilities in non-clinical drug development. Sally Abdelmoaty will primarily focus on the T20K project but will contribute with her deep scientific knowledge to all projects.
Read moreCyxone receives in total SEK 21.8 million in proceeds from fully utilized investment option agreement with Dr. Kalev Kask
October 2, 2020 08:47 (CEST)RegulatoryCyxone AB (publ), a Swedish biotech company dedicated to developing improved treatments for autoimmune diseases, announces today that the investment option agreement with Dr. Kalev Kask has been fully utilized through a third and final utilization of the investment option. The three directed share issues carried out under the agreement brings the company a gross proceed of SEK 21.8 million in total, whereof, SEK 1.8 million has already been received through earlier utilizations. This will cover most of the costs for the planned phase 2 clinical study of Rabeximod in Covid-19 patients. This means that other ongoing projects will not be affected. The study is planned to start in the fourth quarter of 2020.
Read moreCyxone revises the development plan for Rabeximod
September 24, 2020 23:30 (CEST)RegulatoryCyxone AB (publ), a Swedish biotech company dedicated to developing improved treatments for autoimmune diseases, announces today that it has initiated a process to optimize the development plan for Rabeximod. This initiative is based on valuable input from the company’s new senior medical advisors, updated market intelligence and the opportunity to prolong market exclusivity through newly filed patent applications. In parallel, the company is preparing a phase 2 clinical study of Rabeximod in Covid-19 patients, with a potential initiation already in the fourth quarter of 2020.
Read more